Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 4 study of methyl aminolevulinate photodynamic therapy for actinic keratosis using Hydrosun 505 versus Aktilite 128
2005-002983-27Phase 4Completed
- Sponsor
- University Hospital RWTH Aachen
- Start
- Oct 2005
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methyl aminolevulinate in actinic keratosis (AK) (2 arms), sponsored by University Hospital RWTH Aachen. Primary endpoint: Final assessment after one year. Started Oct 2005; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2005-002983-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002983-27.